RFWD3 modulates response to platinum chemotherapy and promotes cancer associated phenotypes in high grade serous ovarian cancer
Sarah Taylor(National Institutes of Health), Mark J. Arends(Edinburgh Cancer Research)
Cited by 3
Related Papers
First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma
|Journal of Translational Medicine|2018|540
BRAF inhibitor resistance mediated by the AKT pathway in an oncogenic BRAF mouse melanoma model
|Proceedings of the National Academy of Sciences|2015|143
Mutation analysis of CBP and PCAF reveals rare inactivating mutations in cancer cell lines but not in primary tumours
|British Journal of Cancer|2002|61
Correction to: First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma
|Journal of Translational Medicine|2018|17